Submission & Approval

Accelerated Approval(AA)

An FDA pathway allowing earlier approval based on surrogate or intermediate endpoints for serious conditions.

Usage Examples

The oncology drug received Accelerated Approval based on tumor response rate.
The confirmatory trial is required to verify clinical benefit.
FDA withdrew the Accelerated Approval after the confirmatory trial failed.

What is AA?

Accelerated Approval allows FDA to approve drugs for serious conditions that fill an unmet medical need based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit.

Because approval is based on a surrogate rather than direct clinical benefit, sponsors are typically required to conduct post-marketing confirmatory trials to verify and describe the anticipated clinical benefit. If confirmatory trials fail to verify benefit, or are not conducted diligently, FDA may withdraw approval.

Recent legislation has strengthened FDA's authority to require confirmatory trials and to withdraw approvals when trials fail or aren't completed. The pathway is commonly used in oncology, HIV/AIDS, and rare diseases.

Regulatory Context

This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 314 500, 21 CFR 601 40.

FDAICHEMA

When This Matters

The oncology drug received Accelerated Approval based on tumor response rate.
The confirmatory trial is required to verify clinical benefit.
FDA withdrew the Accelerated Approval after the confirmatory trial failed.

Common Mistakes

Treating submission readiness as a formatting-only check without lifecycle validation.
Using outdated guidance references across modules and summaries.
Missing cross-functional review between RA, CMC, and quality before submission.

Related Regulations

21 CFR 314 50021 CFR 601 40

Frequently Asked Questions

A surrogate endpoint is a marker (lab test, physical sign, etc.) that is reasonably likely to predict clinical benefit but is not itself a direct measure of how a patient feels, functions, or survives.

FDA may initiate proceedings to withdraw the approval. Recent legislation has streamlined this process, and several Accelerated Approvals have been withdrawn when confirmatory data didn't verify benefit.

No, while oncology drugs frequently use this pathway (based on tumor response), it's available for any serious condition with unmet need. It has been used for HIV drugs, rare diseases, and other indications.